Скачать или смотреть BLUE JET HEALTHCARE LIMITED Q4 FY24 Earnings concall

Q4 & FY24 Earnings Highlights

Vv Revenue from operations for Q4FY24 stood at Rs. 1,839 mn which de-grew 15.3% on YoY basis compared to Rs. 2,173 mn in
QAFY23.
Vv EBITDA for the quarter came at Rs. 531 mn, which was down 24.5% YoY compared to Rs. 703 mn in Q4FY23.
Vv EBITDA margin for the quarter came at 28.8% as compared to 32.4% in Q4FY23, down 351 bps YoY.
v PAT for the quarter was at Rs. 397 mn, which de-grew 29.5% YoY compared to Rs. 562 mn in Q4FY23.

Vv PAT margin for the quarter came at 21.6% as compared to 25.9% in Q4FY23, down 432 bps YoY.

v Revenue from operations for FY24 stood at Rs. 7,116 mn compared to Rs. 7,210 mn in FY23
v EBITDA for FY24 came at Rs. 2,292 mn up 4.6% YoY compared to Rs. 2,190 mn in FY23.
v EBITDA margin for FY24 was at 32.2% as compared to 30.4% in FY23, up 183 bps YoY.
Y PAT for FY24 stands at Rs. 1,638 mn up 2.3% YoY compared to Rs. 1,600 mn in FY23.
Y PAT margin for FY24 was at 23.0% as compared to 22.2% in FY23, up 80 bps YoY.
Y Robust Liquidity with Cash & Cash equivalent / Liquid investments stands at Rs 3,352 Mn for the year.
v¥ Maiden Dividend declared Rs. 1/- per share of face value of Rs. 2/- i.e 50 % which is subject to the approval of shareholders at the ensued Annual General meeting of the Company.

Business Highlights

¥ Launch took place in the PI/API product category, which facilitated increase in reveues. The Innovator has received
label expansion and certain label exclusions. We have built sustainability in business where there is no uncertainty in
the products.
Y Dispatched an lodinated Contrast Media product for validation.
Y The Artificial Sweetener business experienced headwinds during the year due to the imports from China.
Y One new production block at Ambernath facility is undergoing validations, and the facility will be commercialized soon.